Drug Profile
Bryodin 2
Latest Information Update: 17 Jan 2008
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics; Antivirals
- Mechanism of Action Immunomodulators; Protein synthesis inhibitors; Ribosomal protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Immunological disorders; Viral infections
Most Recent Events
- 19 Feb 2001 No-Development-Reported for Cancer in USA (unspecified route)
- 19 Feb 2001 No-Development-Reported for Immunological disorders in USA (unspecified route)
- 19 Feb 2001 No-Development-Reported for Viral infections in USA (unspecified route)